4.5 Article

Disease Profile and Oncologic Outcomes After Delayed Diagnosis of Human Papillomavirus-Associated Oropharyngeal Cancer

Journal

OTOLARYNGOLOGY-HEAD AND NECK SURGERY
Volume 165, Issue 6, Pages 830-837

Publisher

SAGE PUBLICATIONS INC
DOI: 10.1177/01945998211000426

Keywords

HPV; human papillomavirus; oropharynx; oropharyngeal cancer; delayed diagnosis; diagnostic delay; squamous cell; outcomes; prognosis

Ask authors/readers for more resources

Delayed diagnosis of HPV(+)OPSCC is associated with a greater burden of disease at presentation, but oncologic outcomes remain favorable across treatment modalities.
Objective Diagnostic delay in human papillomavirus-associated oropharynx squamous cell carcinoma (HPV(+)OPSCC) is common due to nonspecific symptoms. We aim to describe the disease burden and oncologic outcomes of patients with HPV(+)OPSCC diagnosed >12 months after symptom onset. Study Design This is a retrospective cohort study of HPV(+)OPSCC patients receiving intent-to-cure treatment (including surgery +/- adjuvant therapy or primary chemoradiation). Setting 2006-2016, tertiary care center. Methods Tumor stage was compared between patients with and without delayed diagnosis using chi(2) tests. Kaplan-Meier survival analysis with univariate and multivariable Cox regressions were used to determine the effect of diagnostic delay on oncologic outcomes. Results In total, 664 patients were included. Compared to patients diagnosed <12 months from symptom onset (n = 601), those diagnosed at >12 months (n = 63) were more likely to have T4 disease and higher overall American Joint Committee on Cancer (AJCC) clinical stage at presentation (P < .01 for both). At 5 years, rates of overall survival, cancer-specific survival, progression-free survival, and distant metastases-free survival in the delayed diagnosis cohort were 80%, 90%, 80%, and 89%, respectively. A >12-month delay in diagnosis did not significantly impact overall survival (adjusted hazard ratio [aHR], 1.16; 95% CI, 0.58-2.31), cancer-specific survival (aHR, 0.83; 95% CI, 0.29-2.39), progression-free survival (aHR, 1.15; 95% CI, 0.56-2.37), or distant metastases-free survival (aHR, 1.00; 95% CI, 0.42-2.40) after adjusting for age, sex, and clinical AJCC stage (P > .05 for all). Conclusions Delayed diagnosis of HPV(+)OPSCC is associated with greater burden of disease at presentation, but oncologic outcomes remain favorable across treatment modalities. When appropriate, intent-to-cure therapy should be pursued despite diagnostic delay.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available